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ABSTRACT
Introduction: Previous reports have shown epithelial–mesenchymal transition (EMT) as an active process
that contributes to small airway fibrotic pathology. Myofibroblasts are highly active pro-fibrotic cells that
secrete excessive and altered extracellular matrix (ECM). Here we relate small airway myofibroblast
presence with airway remodelling, physiology and EMT activity in smokers and COPD patients.
Methods: Lung resections from nonsmoker controls, normal lung function smokers and COPD current
and ex-smokers were stained with anti-human α-smooth muscle actin (SMA), collagen 1 and fibronectin.
αSMA+ cells were computed in reticular basement membrane (Rbm), lamina propria and adventitia and
presented per mm of Rbm and mm2 of lamina propria. Collagen-1 and fibronectin are presented as a
percentage change from normal. All analyses including airway thickness were measured using Image-pro-
plus 7.0.
Results: We found an increase in subepithelial lamina propria (especially) and adventitia thickness in all
pathological groups compared to nonsmoker controls. Increases in αSMA+ myofibroblasts were observed
in subepithelial Rbm, lamina propria and adventitia in both the smoker and COPD groups compared to
nonsmoker controls. Furthermore, the increase in the myofibroblast population in the lamina propria was
strongly associated with decrease in lung function, lamina propria thickening, increase in ECM protein
deposition, and finally EMT activity in epithelial cells.
Conclusions: This is the first systematic characterisation of small airway myofibroblasts in COPD based on
their localisation, with statistically significant correlations between them and other pan-airway structural,
lung function and ECM protein changes. Finally, we suggest that EMT may be involved in such changes.
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The Global Initiative for Chronic Obstructive Lung Disease (GOLD) has defined COPD as a disease state
characterised by airflow limitation that is not entirely reversible. The airflow limitation is usually both
progressive and associated with an abnormal (inflammatory) response of the “lungs to noxious particles or
gases” [1]; by far the most common of these in Western countries being cigarette smoke. The major
pathological changes of COPD are observed in the airways, and functionally are mainly fibrosis and
destruction in the small airways (SA) wall [2]. Emphysema of the peribronchial lung parenchyma occurs
∼10 years after SA obstruction can be detected [3, 4], and predominantly in the areas initially affected by
air trapping [5].
In spite of an existing dogma that the airway wall is “inflamed” in COPD, the most comprehensive study
on this, from our lab, demonstrated relative hypocellularity in the airway walls of both large and small
airways, but in both areas the “stromal” (mesenchymal) cell “fibroblast”-like population was the largest cell
component [6, 7]. In the current study, we wished to further relate changes in a subpopulation of these
stromal cells, namely myofibroblasts, to airway wall thickening and deposition of strategic representative
extracellular matrix (ECM) proteins. Our focus was on SA tissue for these analyses, as this is the
predominant site of functional airflow changes in COPD. Because of this we have strongly emphasised the
relationship of these pathological small airway changes to appropriate measures of airflow obstruction [8].
Myofibroblasts are motile and contractile cells, with a high expression of α-smooth muscle actin (αSMA)
protein. Previous studies in COPD evaluating expression of this protein marker for myofibroblasts in
resected human airway tissue have been variable [9] in large and SA tissue. In contrast, findings from
in vitro studies with fibroblasts isolated from the distal end of the airways from COPD patients did show
increased contractile properties associated with increased myofibroblast numbers [10]. These findings
suggest that myofibroblasts may be important in both large and small airways.
In the current study, we used anti-αSMA antibody immunochemistry to identify and quantify the SA wall
myofibroblast population, taking care to dissociate them from smooth muscle cell bundles. In addition, we
have descriptively analysed the localisation of these cells in the SA wall tissue sublayers. As mentioned, we
have analysed whether the changes in these cell types have likely direct implications for airflow limitation
in COPD through airway wall tissue remodelling, thickening and “scarring”, i.e. re-organisation of the
ECM. Furthermore, we wished to evaluate further here whether these remodelling changes in the SA of
smokers and COPD patients are likely to be driven by the presence of SA epithelial–mesenchymal




The Tasmanian Health and Medical Human Research Ethics Committee approved the study (H0012374).
Tissues from normal nonsmoker controls were obtained from the James Hogg Lung Registry, the
University of British Columbia with approval from the Providence Health Care Research Ethics Board
(H00-50110).
Subject demographics
Resected tissues containing multiple SAs suitable for analysis (<2 mm internal diameter) from 40 patients
were included (table 1). These non-normal subjects all had primary nonsmall cell lung cancer, with an
approximately equal distribution of squamous and adenocarcinoma. 20 patients demonstrated
mild–moderate GOLD stage I or II, of whom nine were COPD current smokers (CS) and 11 were COPD
ex-smokers (ES) (>1 year smoking cessation). 11 individuals were normal lung function smokers (NLFS).
Tissue from 10 normal controls (NC) was obtained from the tissue bank at the University of British
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Columbia. Subjects with other respiratory diseases, a history of a recent acute exacerbation of COPD and
those on systemic or inhaled corticosteroids were excluded from the study. The surgically resected material
was taken well away from the primary tumour and contained no cancer-involved SA or related pneumonitis.
Immunostaining
Sections were cut at 3 μm from individual paraffin-embedded blocks and immunostained for mouse
monoclonal anti-αSMA (M0851, Dako; 1:400 dilution), mouse polyclonal anti-collagen-1 (AB34710,
Abcam; 1:250 dilution) and polyclonal rabbit fibronectin (A0245, Dako; 1:1000 dilution) for 90 min at
room temperature. Species-appropriate isotype-matched immunoglobulin G (X0931 clone DAK-GO1;
Dako) was incorporated. Bound antibodies were elaborated using peroxidase-labelled Envision (K4001;
Dako) and diaminobenzidine (K3468; Dako). In addition, we incorporated an overlapping group of
smoker and COPD tissues from a previous study [15] in which SAs had been stained in the same way as
described earlier for S100A4 and vimentin, both EMT activity markers in epithelium, where they are
co-expressed with epithelial proteins.
Quantification of SA tissue staining
Image analysis was performed with a Leica DM 2500 microscope (Leica Microsystems, Germany), Spot
Insight-12 (Spot Imaging Solutions, USA) digital camera and Image Pro Plus 7.0 (Media Cybernetics,
USA) software. Firstly, as many images as possible were taken of the airway wall from multiple areas. The
study included epithelium plus submucosal layers down to the alveolar interface, and strictly avoided
overlapping of tissue. For each of the measurements, eight randomly selected images including the full
airway thickness from at least eight good pictures.
Assessing SA wall thickness
For the study of SA thickness, three to four SAs per patient were analysed, and of the total images, eight
were selected using an online random number generator programme (www.stattrek.com). These tissue
pictures were each divided into three subepithelial regions: the lamina propria (the area between the lower
limit of the reticular basement membrane (Rbm) and the upper margin of the muscle layer); the smooth
muscle layer; and the adventitia (the area between lower margin of the muscle to the margin of the
alveolar tissue interface) (figure 1a and b). Using Image ProPlus version 7.0 software tools, for each layer
thickness a line was drawn at each extreme layer margins, i.e. at the interface with the ones above and
below. Based on tissue orientiation, either the horizontal, vertical or curved tool was selected, and the
average distance between the margins was calculated using an automated distance calculator programme
within the Image ProPlus 7.0 software. The analysis was conducted by an observer (MSE) who was
blinded to subject and clinical group.
Quantification of myofibroblasts and ECM proteins
αSMA+ cells with a fibroblast-like morphology were classified as myofibroblasts and enumerated in the SA
wall Rbm, lamina propria and adventitia regions. Such αSMA+ cells in the Rbm were enumerated as cells
per mm length of the Rbm, while for the lamina propria and adventitia the cells were enumerated as per
mm2 of the respective area. For the expression of ECM “scar” proteins collagen-1 and fibronectin, diffuse
brown staining was selected in the area of interest drawn manually for both lamina propria (the area
between the lower limit of the Rbm and the upper margin of the muscle layer) and adventitia (the area
between lower margin of the muscle to the margin of the alveolar tissue interface) regions using tissue
TABLE 1 Patient demographics
NC NLFS COPD-CS COPD-ES
Subjects 10 11 9 10
Age years 50 (19–73) 69 (52–79)** 65 (59–78)** 68 (56–85)**
Smoking history pack-years NS 27 (0.3–40) 30 (2–48) 30 (2–58)
FEV1/FVC %
# N/A 76 (70–90) 66 (59.9–70) 64 (55–69)
FEF25–75%
# N/A 79 (47–116) 37 (28–47) 41 (20–55)
Data are presented as n or median (range). NC: normal control; NLFS: normal lung function smoker;
COPD-CS: COPD current smoker; COPD-ES: COPD ex-smoker; FEV1: forced expiratory volume in 1 s; FVC:
forced vital capacity; FEF25–75%: forced expiratory flow at 25–75% of FVC; NS: nonsmokers; N/A: not
available. #: post-bronchodilator values after 400 µg salbutamol. **: p<0.01 over NC (ordinary one-way
ANOVA followed by Dunnett’s multiple comparison test).
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analysis software Image ProPlus 7.0. Furthermore, the software was used to generate a ratio of the
collagen-1 and fibronectin staining in each selected area of interest, which is presented here as percentage
staining. All analyses were conducted by an observer (MSE) who was blinded to clinical group and other
tissue pathology measures.
Statistical analysis
For all cross-sectional data, we tested their normal distributions using the D’Agostino–Pearson omnibus
normality test. Nonparametric ANOVAs were performed using the Kruskal–Wallis test, which compared
medians/ranges across all the groups of interest; specific group differences with correction for multiple









































































































FIGURE 1 Representative images of the full airway wall thickness in the small airway wall of a) normal
control (NC) and b) COPD. An increase in thickness was observed in the clinical (smoker/COPD) groups in the
c) lamina propria (LP), d) adventitia and e) smooth muscle (SM) layer. NLFS: normal lung function smoker;
COPD-CS: COPD current smoker; COPD-ES: COPD ex-smoker. Scale bars=50 μm. **: p<0.01, ***: p<0.001.
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Spearman’s rank test. These statistical analyses were completed using GraphPad Prism V8.0, with a
p-value ⩽0.05 being considered significant.
Results
Increased SA wall component thickness in smokers and COPD
Both the lamina propria and adventitia were significantly thicker in COPD subjects, with the lamina
propria showing at least a 10-fold change overall compared to normal controls, whereas in the adventitial
areas there was a two- to three-fold thickening (figure 1). The muscle layer too was thickened, but only by
50% (figure 1e). All these changes together were reflected in a substantial increase in total SA thickness in
COPD, and almost equally in smokers, except in the lamina propria, where there appeared to be some
interaction between active smoking and COPD.
Airway thickening versus airflow measures
There was a significant negative correlation between increased SA wall thickening and decrease in
airflow-related lung function in the COPD groups combined, but only with lamina propria subepithelial
layer (figure 2a and b).
αSMA+ myofibroblasts in SA
Significant increases in SA αSMA+ myofibroblasts were observed throughout the airway wall in the
smokers and COPD groups, but most consistently in the latter. The density and increase in myofibroblasts
were especially more striking in the lamina propria and in actively smoking COPD. The increases in
myofibroblast numbers in the SA lamina propria of smokers/COPD tissues were not uniform, but the cells
were most concentrated in a shallow band just deep to the Rbm (figure 3).
ECM deposition in SA wall
There was an overall increase in the key ECM proteins, collagen-1 and fibronectin in the airway wall in all
three smoker and COPD groups, with fibronectin changes being the most pronounced (figure 4).
Empirically, there were both smoking and COPD effects, with greatest effects seen in the COPD-CS group.
In comparison to percentage collagen-1 expression in the lamina propria (1.5-fold increase), the increase
in the adventitia was much greater (five- to six-fold) in smokers and COPD patients compared to NC
(figure 4a and c). This distribution difference was not seen for fibronectin, where the fold increase was
more uniform (figure 4b and d).
Correlation of SA myofibroblasts with airflow physiological measures, and with SA wall lamina
propria thickening
We present a complex set of correlations to show together the relationships between myofibroblast
numbers in the Rbm and the lamina propria against airflow in the three clinical groups. Although group
numbers are rather small, there was still a significant or near significant correlation between myofibroblast
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FIGURE 2 Correlation between airway wall thickness and lung function indices: a) forced expiratory volume in
1 s (FEV1)/forced vital capacity (FVC) and b) forced expiratory flow at 25–75% of FVC (FEF25–75%) (more specific
for small airways (SA)) in the combined COPD groups. LP: lamina propria.
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NC NLFS COPD-CS COPD-ES
FIGURE 3 Representative images of α-smooth muscle actin (SMA)+ cells in the airway wall of a) normal control (NC), normal lung function
smoker (NLFS) and COPD current (CS) and ex-smokers (ES). Increase in small airway (SA) αSMA+ cells were observed in all three sublayers of
the subepithelial areas of the small airway wall: b) reticular basement membrane (Rbm); c) lamina propria (LP); and d) adventitia. Scale























































































































FIGURE 4 Representative images of collagen-1 and fibronectin deposition by percentage area in the airway wall of a) normal control (NC), normal
lung function smoker (NLFS) and COPD current (CS) and ex-smokers (ES), with increases in percentage collagen-1 and fibronectin expression in
pathological groups in both the b,d) lamina propria (LP) and c,e) adventitia, with both CS and COPD effects. SA: small airway. Scale bars=50 μm.
*: p<0.05, **: p<0.01, ***: p<0.001.
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numbers versus decreases in airflow (obstruction), both as forced expiratory volume in 1 s (FEV1)/forced
vital capacity (FVC) ratio and forced expiratory flow at 25–75% of FVC, in both COPD groups, but not in
the NLFS (figure 5a–d). Again, relationships were most consistently seen between airflow obstruction and
tissue myofibroblasts in the currently smoking COPD group. Regression analysis between myofibroblast
density in the SA lamina propria region and lamina propria thickness in all pathological groups (including
current and ex-smokers) (figure 5e) showed a very similar picture, but suggesting both a smoking and
COPD effect.
Correlation of percentage collagen-1 and fibronectin with lung function and SA wall lamina
propria thickness in smoker/COPD groups
A significant correlation was seen between collagen-1 deposition in the SA lamina propria and lung
function in the COPD-CS, but this was absent in the COPD-ES group. However, no significant correlation
was found between fibronectin deposition in SA lamina propria or lung function (table 2). The percentage
by area tissue for collagen-1 expression in the lamina propria was significant and positively correlated with
lamina propria thickness in COPD (both -CS and -ES) patients, but, in contrast, this was not the case in
the NLFS group, although their lamina propria thickness was increased, as already shown (table 2).
Notably, and contrary to collagen-1 expression, fibronectin percentage area positivity correlated to
increasing normal smoker lamina propria thickness only and not in the COPD groups (table 2).
Correlation of EMT markers in SA wall cells versus number of αSMA+ myofibroblasts and airway
thickening
EMT-marker expression in basal epithelial cells showed a postive association with αSMA+ myofibroblasts
in Rbm (figure 6a and b) of the SA wall in combined COPD and NLFS groups with a ratio of ∼4:1.
Additionally, within the Rbm there was a relationship between S100A4 and αSMA+ cells with a ratio of
∼1.5:1, suggesting a transition of mesenchymal-marker positive cells towards myofibroblasts, with αSMA
cell expression thought to represent a late manifestation of the EMT process. Equally notably, there was a
positive relationship between basal epithelial cell EMT activity, as indicted by both S100A4 and vimentin
expression, and the (enhanced) thickness of the lamina propria.
Discussion
A core finding in this study was the increase in αSMA+ myofibroblasts in the SA wall of COPD patients
and its association with a major increase in the lamina propria sublayer thickness. In addition, there were
increases in thickness of the Rbm, muscle layer and adventitia. These changes in the myofibroblast
population were also directly related to significant pathological changes in the ECM scar proteins,
collagen-1 and fibronectin. In context to our earlier findings of EMT activity in SA epithelium in smokers
and COPD, we believe that such transformation could lead to an increase in fibroblast or myofibroblast
population. Both EMT activity and what we suggest to be secondary changes in the myofibroblast
population and consequential lamina propria thickening were also related to obstructive airflow limitation.
Thus, from our current and previous observations, we suggest that EMT may play a crucial role in the SA
wall remodelling which leads to SA narrowing and ultimately obliteration, as we and others have suggested
previously [12, 14, 16, 17].
It has been accepted that one of the principal causes for airflow limitation in COPD is the airway wall
tissue remodelling through re-organisation of the ECM [18]. In the current study, we analysed two
important markers of ECM pathology, collagen-1 and fibronectin, both of which have been described as
colocalised to areas with increased proliferation of myofibroblasts in COPD [19, 20]. Although we found
significant increases in percent expression of both these ECMs, there were also marked differences between
fibronectin and collagen-1 expression in various SA sublayers. Furthermore, both ECM protein expressions
were increased in smokers, but more so in COPD-CS, i.e. both factors seemed to have influence in disease
progression. Understanding potential consequences of these anatomic variations will need further effort,
but we found that collagen-1 but not fibronectin in lamina propria was associated with airflow obstruction
in COPD. For fibronectin, its cellular immune-modulatory roles may be more important than structural
ones [21].
Our current observation of an increase in collagen-1 is in agreement with the earlier studies by HARJU
et al. [20] in SA tissues where an overall increase in both collagen-1 and -3 subtypes in GOLD stages I
and II COPD were observed in the SA lamina propria. Both these studies contrast with observations by
ANNONI et al. [22], who suggested a decrease in collagen-1 deposition in SA in mild–moderate COPD
patients, although they too found an increase in fibronectin in both smokers and COPD patients.
Furthermore, ECM changes seemed to regress in COPD-ES, and indeed relationships to lung function
were significant in current-smoking COPD patients, but not ex-smokers. The cause of such regression
https://doi.org/10.1183/23120541.00876-2020 7
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FIGURE 5 Correlations between α-smooth muscle actin (SMA)+ myofibroblasts in the a, c) reticular basement membrane (Rbm) and b, d) lamina
propria (LP) of the three smoking/COPD groups (normal lung function smoker (NLFS) and COPD current (CS) and ex-smokers (ES)) and indices of
airflow, done independently: a, b) forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio and c, d) forced expiratory flow at 25–75%
of FVC (FEF25–75%); e) correlation between number of myofibroblasts and thickness of LP among the combined pathological groups. SA: small
airway; r′: Spearman’s r.
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since quitting would seem to be an important research question and needs wider attention in the research
community.
ECM-producing myofibroblasts have a spindle-shaped morphology and are highly contractile due the
presence of αSMA microfilaments [23, 24]. Surprisingly, few reports have been published that our current
TABLE 2 Correlation of extracellular matrix proteins (collagen-1 and fibronectin) with lung
function and small airway lamina propria thickness
NLFS COPD-CS COPD-ES
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NLFS: normal lung function smoker; COPD-CS: COPD current smoker; COPD-ES: COPD ex-smoker; FEV1:
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FIGURE 6 Correlations between the epithelial–mesenchymal transition (EMT) marker S100A4+ expression in
the a) basal epithelial cells and b) reticular basement membrane (Rbm), with α-smooth muscle actin (SMA)+
cells within both small airway (SA) wall and the Rbm; and between the two EMT markers c) S100A4 and
d) vimentin expressed in basal epithelial cells and lamina propria (LP) thickening.
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data could be compared to. Our finding of an increase in αSMA+ myofibroblasts (on morphology criteria)
is in contrast to that of KARVONEN et al. [25], who showed a decrease in expression αSMA+ cells in the
bronchioles of COPD patients compared to nonsmoker controls. The differences in the findings are
probably due to the counting strategy and area under consideration. Thus, while KAROVNEN et al. counted
αSMA+ cells in the whole of the subepithelial wall, in the current study we took each sublayer in turn.
Indeed, KAROVNEN et al. considered the Rbm and the muscle layer as part of the lamina propria for SA.
However, our findings are similar to those of HARJU et al. [20], who provided a descriptive analysis of the
SA tissue and evidence of colocalisation of αSMA+ cells with collagen subtypes as well as mesenchymal
markers such as vimentin in the SA wall. Like us, they suggested that αSMA+ myofibroblasts could be
responsible for the increased accumulation of collagen-1 and fibronectin in the SA lamina propria of
COPD patients, and, like us, others have suggested that myofibroblasts are responsible for airway wall
thickening secondary to ECM accumulation (supplementary figure S1) [20].
We have taken these matters substantially further than previous reports, observing physiological measures
of reduced airway calibre with increasing myofibroblast density accompanying changes in ECM, and
suggesting possible involvement of this cell type in SA remodelling and narrowing and ultimately
obliteration [2, 26]. Therefore, we should emphasise that the airways that we are studying are the
“survivor” airways from this obliterative SA process, and we are looking at glimpses of pathogenic
processes going on for many years in any one individual.
As mentioned, our group’s previous data [15] suggested that the underlying mechanism for airway wall
remodelling is through the induction of EMT [11, 27], as part of a broader epithelial-gene reprogramming
[28, 29]. We now suggest recruitment of myofibroblasts to the underlying airway wall from the
mesenchymally transitioned basal stem cells of the epithelium. We have previously demonstrated a strong
relationship between markers of epithelial EMT activity, such as S100A4 and vimentin expression in these
basal cells, with increasing airway obstruction [11, 15]. Transforming growth factor (TGF)-β1 pathways are
likely to contribute to driving EMT in COPD, via nuclear transcription factors such as pSMAD2/3 with
reduction in the inhibitory SMAD7 [13, 30]. Interestingly, TGF-β1 pathways are also suggested to play a
crucial role in the development of myofibroblasts from tissue fibroblasts through activation of the SMAD
pathway [26, 31], so although we believe EMT to be a key mechanism in COPD pathogenesis [32], it is
unlikely to be the only growth factor driven mechanism operating throughout the whole thickness of the SA
wall [33]. In addition to the TGF-β1 pathway, we and others have previously shown that the transcription
factor clusters of β-catenin/Snail1/Twist is upregulated and with nuclear translocation in smokers and
COPD, and their expression is closely related to both EMT activity and lung function [28, 34, 35].
There are limitations to our study. The numbers of individual subjects contributing tissue samples per
clinical group were relatively small due to study logistics, but even so many of the findings are statistically
robust for the most part, and consistently so, emphasising the strength of the signals obtained.
Furthermore, this study included a wider age range in the normal control subjects, with median age
significantly lower than the pathological subjects (table 1). As the age of the control subjects is
significantly lower than the age of patients with COPD, we cannot exclude that our observations partly
result from the possible contribution of age in addition to smoking and disease. We did find that smokers
with normal lung function had thick airway walls, increased myofibroblast numbers and significantly
higher ECM changes compared to normal subjects and closer to levels of patients with COPD [36].
Different studies have reported morphological changes in the airways with normal ageing, which mainly
includes progressive decrease in cartilage thickening and airway dilation, but interestingly in CT image
analysis of the small airways, no linear progression in airway wall thickening and ageing was observed in
normal subjects, especially between the fourth and sixth generation airways, which were indeed thicker in
patients with COPD [37–39]. Clinical features such as air trapping seems to be common between ageing
lungs and COPD. Another generic problem in this method of tissue research is that the COPD-CS SA
were obtained from cancer patients, and thus some confounding by this disease pathology and secondary
pneumonitis could conceivably be present. However, all the tissue used was carefully taken under
microscopy by an experienced pathologist well away from cancer-involved areas.
Conclusion
We know from the work of HOGG et al. [8] and indeed earlier studies, that a large number of SA will have
been obliterated, leaving just a scar, by the time a smoker has reached the degree of airflow obstruction
that can be classified as COPD. Our regression analyses showed that despite the cumulative damage that
has already occurred, the activity of current processes are still likely to reflect the totality of this
pathophysiology. Thus, our conclusions reflect not only acute pathology relevant to an arbitrary point in
time for each individual when samples were obtained, but the totality of the data allows a quite profound
representation of the whole history of the core pathological process in smoking-related COPD going back
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over many years. Our data would support the logic and need for treatment as early as possible and
identifies possible new pathophysiological targets for therapy [40].
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